Vertex Pharmaceuticals Incorporated (VRTX)

Check out top investors' recommendation for VRTX
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
214.20
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Its products include telaprevir for the treatment of adults with genotype 1 hepatitis C virus (HCV) infection, which is marketed in the United States and Canada under the INCIVEK brand name; and ivacaftor for the treatment of cystic fibrosis that is marketed in the United States, Canada, and Europe under the KALYDECO brand name. The company, through its collaboration agreement with Janssen Pharmaceutica, N.V., also markets telaprevir in Europe and other countries in Janssen's territories under the INCIVO brand name, as well as in Japan under TELAVIC brand name. It is also developing drug candidates for the treatment of cystic fibrosis, including VX-809, which is in Phase III clinical trial and VX-661 that is in Phase II clinical trial; and drug candidates for the treatment of HCV infection, such as VX-135 (ALS-2200), which is in Phase II clinical trial and VX-222 that is in Phase II clinical trial. In addition, the company develops VX-509, which is in Phase II clinical trial for the treatment of autoimmune disease; and VX-787 that is in Phase II clinical trial for the treatment of influenza. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Sector:
Industry:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Andrew Fein Chardan Capital Markets Buy   Nov 28, '18     220.00  Nov 28, '19  N/A 
Alethia Young Deutsche Bank Securities Buy   Nov 27, '18     217.00  Nov 27, '19  N/A 
Edward Tenthoff Piper Jaffray Buy   Nov 27, '18     217.00  Nov 27, '19  N/A 
Geoff Meacham JPMorgan Buy   Nov 26, '18     200.00  Nov 26, '19  N/A 
Alethia Young Deutsche Bank Securities Buy   Oct 10, '18     217.00  Oct 10, '19  N/A 
Edward Tenthoff Piper Jaffray Buy   Sep 06, '18     230.00  Sep 06, '19  N/A 
Robyn Karnauskas Deutsche Bank Securities Buy   Jul 30, '18     206.00  Jul 30, '19  N/A 
Liisa Bayko JMP Securities Buy   May 31, '18     211.00  May 31, '19  N/A 
Michael Yee RBC Capital Markets Buy   May 31, '18     195.00  May 31, '19  N/A 
Brian Abrahams Wells Fargo Securities, Llc Buy   Apr 04, '18     199.00  Apr 04, '19  N/A 
Geoff Porges High Peaks Buy   Feb 01, '18     190.00  Feb 01, '19  N/A 
Geoff Meacham JPMorgan Buy   Feb 01, '18     200.00  Feb 01, '19  N/A 
Robyn Karnauskas Deutsche Bank Securities Buy   Feb 01, '18     203.00  Feb 01, '19  N/A 
Edward Tenthoff Piper Jaffray Buy   Feb 01, '18     212.00  Feb 01, '19  N/A 
Brian Skorney Brean Murray, Carret & Co. Buy   Jan 31, '18     200.00  Jan 31, '19  N/A 
Anthony Butler Barclays Buy   Jan 31, '18     190.00  Jan 31, '19  N/A 
Cory Kasimov JPMorgan Buy   Jan 08, '18       Jan 08, '19  N/A 
Ying Huang Barclays Buy   Jan 05, '18     180.00  Jan 05, '19  N/A 
Michael Yee RBC Capital Markets Buy   Jan 03, '18     185.00  Jan 03, '19  N/A 
Ian Somaiya Piper Jaffray Buy   Jan 02, '18     184.00  Jan 02, '19  N/A 
< previous12345678